Development of a sensitive ELISA for the quantification of human tumour necrosis factor-α using 4 polyclonal antibodies

European Cytokine Network

Volumn 16, Issue 3, 2005, Pages 215-222

  Grebenchtchikov, Nicolai ^a   Van Der Ven Jongekrijg, Johanna ^a   Pesman, Gerard J ^a   Geurts Moespot, Anneke ^a   Van Der Meer, Jos W M ^a   Sweep, Fred C G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ELISA; TNF

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN Y; IMMUNOGLOBULIN Y ANTIBODY; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN;

ARTICLE; BIOASSAY; BLOOD ANALYSIS; CHICKEN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RABBIT; SENSITIVITY ANALYSIS; ANIMAL; DRUG ANTAGONISM; DUCK; EVALUATION; GOAT; IMMUNOLOGY; METHODOLOGY; RADIOIMMUNOASSAY; STANDARD; TUBERCULOSIS;

CAPRA HIRCUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES; ANTIBODIES, HETEROPHILE; CHICKENS; DUCKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GOATS; HUMANS; IMMUNOGLOBULINS; RABBITS; RADIOIMMUNOASSAY; REFERENCE STANDARDS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644697404     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Beutler B, Cerami A. The biology of cachectin/TNF-α a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625.
2. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989; 8647; 1122.
3. van Deuren M, Dofferhoff ASM, van der Meer JWM. Cytokines and the response to infection. J Pathol 1992; 168; 349.
4. Weil D. What's new about tumor necrosis factors? Report on the fourth TNF international congress. Eur Cytokine Netw 1992; 3: 347.
5. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262: 6951.
6. Poiesi C, Albertini A, Ghielmi S, Cassani G, Corti A. Kinetic analysis of TNF-alpha oligomer-monomer transition by surface plasma resonance and immunochemical methods. Cytokine 1993; 5: 539.
7. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994; 300: 281.
8. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019.
9. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 12: 151.
10. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323.
11. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531.
12. McLaughlin PJ, Davies HM, Aikawa A. Tumour-necrosis factor in normal plasma. Lancet 1990; 336: 1014.
13. Markham R, Young L, Fraser IS. An amplified ELISA for human tumour necrosis factor alpha. Eur Cytokine Netw 1995; 6: 49.
14. Berkova N, Karawajew L, Korobko V, Behrsing O, Micheel B, Shamborant O, Stutatcheva E, Shingarova L. Development of an enzyme immunoassay for the measurement of tumour necrosis factor-α (hTNF-α) using bispecific antibodies to hTNF-α and horseradish peroxidase. Biotechnol Appl Biochem 1996; 23: 163.
15. Kreuzer KA, Rockstroh JK, Sauerbruch T, Sprengler U. A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-α. J Immunol Methods 1996; 195: 49.
16. Petrovas C, Daskas SM, Lianidou ES. Determination of tumor necrosis factor-α in serum by a highly sensitive enzyme amplified lanthanide luminescence immunoassay. Clin Biochem 1999; 32: 241.
17. Hedayati M, Yazdanparast R, Azizi F. Determination of human tumor necrosis factor α by a highly sensitive enzyme immunoassay. Biochem Biophys Res Commun 2001; 289: 295.
18. Prabhakar U, Eirikis E, Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP™ assay. J Immunol Methods 2002; 260: 207.
19. Engelberts I, Moller A, Schoen GJ, van der Linden CJ, Buurman WA. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 1991; 10: 69.
20. Corti A, Poiesi C, Merli S, Cassani G. Tumor necrosis factor (TNF)-α quantification by ELISA and bioassay: effects of soluble TNF-α TNF receptor (p55) complex dissociation during assay incubations. J Immunol Methods 1994; 177: 191.
21. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; 2: 1229.
22. Meager A, Leung H, Woolley J. Assays for tumour necrosis factor and related cytokines. J Immunol Methods 1989; 116: 1.
23. Cannon JG, Nerad JL, Poutsiaka DD, Dinarello CA. Measuring circulating cytokines. J Appl Physiol 1993; 75: 1897.
24. Riches P, Gooding R, Millar BC, Rowbottom AW. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations. J Immunol Methods 1992; 153: 125.
25. Heney D, Whicher JT. Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Ann Clin Biochem 1995; 32: 358.
26. James K, Milne I, Cunningham A, Elliott SF. The effect of α2-macroglobulin in commercial cytokine assays. J Immunol Methods 1994; 168: 33.
27. Engelberts I, Stevens S, Francot GJM, Van der Linden GJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338: 515. Bjerner
28. Levinson SS. Test interferences from endogenous antibodies. J Clin Ligand Assay 1997; 20: 180.
29. Bjerner J, Bormer OP, Nustad K. The war on heterophilic antibody interference. Clin Chem 2005; 51: 9.
30. Drenth JPH, Van Uum SHM, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JWM. Endurance run increases circulating IL-6 and IL- Ira but downregulates ex vivo TNF-α and IL-1β production. J Appl Phys 1995; 79: 1497.
31. Van der Meer JWM, Endres S, Lonnemann G, Cannon JG, Ikejima T, Okusawa S, Gelfand JA, Dinarello CA. Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro. J Leukoc Biol 1988; 43: 216.
32. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, Benraad T. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAl-1) in breast tumor cytosols. Int J Biol Markers 1997; 12: 6.
33. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AMJ, Sweep CGJ. EORTC Receptor and Biomarker Study Group report: A sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 2000; 15: 184.
34. Grebenchtchikov N, Sweep CGJ, Geurts-Moespot A, Piffanelli A, Foekens JA. Benraad ThJ. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods 2002; 268: 219.
35. Cannon JG, van der Meer JWM, Kwiatkowski D, Endres S, Lonnemann G, Burke JF, Dinarello CA. Interleukin-1 B in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 1988; 7: 457.
36. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307.
37. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983; 2: 709.
38. Meager A, Parti S, Leung H, Woolley J, Peil E, Sidhu S, Roberts T. A two-site sandwich immunoradiometric assay of human lymphotoxin with monoclonal antibodies and its applications. J Immunol Methods 1987; 104: 31.
39. McLaughlin PJ, Elwood NJ, Ramadi LT, Pica MR, McKenzie IFC. Improvement in sensitivity of enzyme-linked immunosorbent assay for tumour necrosis factor. Immunol Cell Biol 1990; 68: 51.
40. Lamb WR, Pumphrey RSH, Brenchley PEC. A peroxidase-linked enzyme immunoassay for tumour necrosis factor alpha utilising alternative colorimetric or chemilumimetric substrates. J Immunol Methods 1992; 155: 215.
41. Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR. Measuring cytokine levels in blood: importance of anticoagulants, processing and storage conditions. J Immunol 1992; 153: 115.
42. Duncombe AS, Brenner MK. Is circulating tumor necrosis factor bioactive? N Engl J Med 1988; 319: 1227.
43. Bendtzen K, Svenson M, Fomsgaard A, Poulsen LK, Hansen MB. Auto-antibodies to IL-1 and TNF-α in normal individuals and in infectious and immunoinflammatory disorders. Prog Leucocyte Biol 1990; 10: 447.
44. Barrera P, Boerbooms AMT, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PNM, van de Putte LBA, van der Meer JW. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor-α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070.